An Extended Terminal Half-Life for Darbepoetin AlfaResults from a Single-Dose Pharmacokinetic Study in Patients with Chronic Kidney Disease not Receiving Dialysis

被引:0
|
作者
Desmond Padhi
Liyun Ni
Blaire Cooke
Rafael Marino
Graham Jang
机构
[1] Amgen Inc.,
来源
Clinical Pharmacokinetics | 2006年 / 45卷
关键词
Chronic Kidney Disease; Darbepoetin Alfa; Endogenous Erythropoietin; Single Subcutaneous Dose; Erythropoietic Agent;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:503 / 510
页数:7
相关论文
共 50 条
  • [21] Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration
    Kawakami, Kazuki
    Takama, Hirotaka
    Nakashima, Daisuke
    Tanaka, Hideji
    Uchida, Eiji
    Akizawa, Tadao
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1101 - 1101
  • [22] Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration
    Kawakami, Kazuki
    Takama, Hirotaka
    Nakashima, Daisuke
    Tanaka, Hideji
    Uchida, Eiji
    Akizawa, Tadao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (02) : 169 - 178
  • [23] Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration
    Kazuki Kawakami
    Hirotaka Takama
    Daisuke Nakashima
    Hideji Tanaka
    Eiji Uchida
    Tadao Akizawa
    European Journal of Clinical Pharmacology, 2009, 65 : 169 - 178
  • [24] Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open-olabel, Australian study
    Disney, Alex
    De Jersey, Peter
    Kirkland, Geoff
    Mantha, Murty
    Charlesworth, John A.
    Gallagher, Martin
    Harris, David
    Gock, Hilton
    Mangos, George J.
    MacMillan, Jamie
    Liu, Wei
    Viswalingam, Ajit
    NEPHROLOGY, 2007, 12 (01) : 95 - 101
  • [25] A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B
    Rampotas, Alexandros
    Desborough, Michael J. R.
    Raza-Burton, Sayma
    Taylor, Stephanie
    Wilkinson, Alice
    Hall, Georgina W.
    Shapiro, Susan
    Curry, Nicola
    HAEMOPHILIA, 2020, 26 (02) : 278 - 281
  • [26] An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study
    Galle, Jan-Christoph
    Claes, Kathleen
    Kiss, Istvan
    Winearls, Christopher G.
    Herlitz, Hans
    Guerin, Alain
    Di Giulio, Salvatore
    Suranyi, Michael G.
    Bridges, Ian
    Addison, Janet
    Farouk, Mourad
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (06) : 2303 - 2311
  • [27] COMPARATIVE ANALYSIS OF PHARMACOKINETIC (PK) STUDY DATA BETWEEN EXTENDED HALF-LIFE (EHL) AND STANDARD HALF-LIFE (SHL) FACTOR PRODUCTS: EXPERIENCE FROM GREEK ADULT HAEMOPHILIA CENTRE
    Christoforou, P.
    Kourampa, A.
    Varaklioti, A.
    Pirpiri, T.
    Balomenou, A.
    Katsarou, O.
    HAEMOPHILIA, 2023, 29 : 61 - 61
  • [28] Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis
    McGowan, Tracy
    Vaccaro, Nicole M.
    Beaver, Jessica S.
    Massarella, Joseph
    Wolfson, Marsha
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (04): : 1006 - 1014
  • [30] An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis
    Winnie Y. Sohn
    Anthony A. Portale
    Isidro B. Salusky
    Hao Zhang
    Lucy L. Yan
    Bella Ertik
    Shahnaz Shahinfar
    Edward Lee
    Bastian Dehmel
    Bradley A. Warady
    Pediatric Nephrology, 2019, 34 : 145 - 154